Neomycin 3.5 mg/g / Polymyxin B10000 USP Units/g / Dexamethasone 1 mg/g Ophthalmic Ointment, 3.5 ...
FDA Drug Recall #D-1580-2019 — Class II — July 12, 2019
Recall Summary
| Recall Number | D-1580-2019 |
| Classification | Class II — Moderate risk |
| Date Initiated | July 12, 2019 |
| Status | Terminated |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | H J Harkins Company Inc dba Pharma Pac |
| Location | Grover Beach, CA |
| Product Type | Drugs |
| Quantity | 97 boxes |
Product Description
Neomycin 3.5 mg/g / Polymyxin B10000 USP Units/g / Dexamethasone 1 mg/g Ophthalmic Ointment, 3.5 g tube, Rx only, Manufactured for H.J. Harkins Company, Inc. dba Pharma Pac by Perrigo Co, Allegan, MI 49010, NDC 52959-0407-01
Reason for Recall
CGMPs Deviations: Insufficient Quality Assurance controls over critical systems in the manufacturing facility.
Distribution Pattern
Distributed in California
Lot / Code Information
Lot #: NPD10RP, Exp 08/19; NPD11RP, Exp 09/19; NPD12RP, Exp 11/19; NPD13RP, Exp 02/20; NPD14RP, Exp 02/20; NPD15RP, Exp 05/20; NPD16RP, Exp 06/20; NPD17RP, Exp 01/21; NPD18RP, Exp 02/21
Other Recalls from H J Harkins Company Inc dba Pharma Pac
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-1246-2020 | Class II | Acetaminophen and Codeine Phosphate 300/30 mg t... | Apr 15, 2020 |
| D-1005-2020 | Class II | Acetaminophen 500 mg tablet packaged in a) 30-c... | Mar 6, 2020 |
| D-0793-2020 | Class II | Ranitidine, 150 mg Tablets, a) 7 count, b) 14 c... | Jan 6, 2020 |
| D-1429-2019 | Class II | Acetaminophen Children's Liquid, 160 mg/5 mL, 4... | Jun 24, 2019 |
| D-1430-2019 | Class II | Diphenhydramine HCL Liquid, 12.5 mg/5 mL, 4 oz ... | Jun 24, 2019 |
Frequently Asked Questions
cGMP stands for Current Good Manufacturing Practice — the FDA's regulations governing drug manufacturing quality. A cGMP recall means the company failed to follow required manufacturing standards. This could involve inadequate testing, poor environmental controls, documentation failures, or process deviations. cGMP recalls do not always mean the product is directly harmful — in many cases, quality records are insufficient to confirm the product meets specifications. However, the FDA requires a recall because without proper documentation, product quality cannot be assured. These are often Class II or Class III recalls.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.